Cytori Therapeutics, Inc. (CYTX) Cell Therapy Reduces Hand Disability And Pain In Scleroderma Patients
8/12/2014 11:08:45 AM
SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ: CYTX) today announced that six month outcomes from a 12 patient independent investigator-initiated study using Cytori Cell Therapy to treat scleroderma have been published in the Annals of Rheumatic Disease. The article is currently available online.
Data from the study indicated that treatment with Cytori Cell Therapy was safe and well tolerated through six months. In addition, the data indicated an approximately 50% average improvement across four key, validated endpoints used to assess the clinical status in patients with systemic scleroderma with impaired hand function at two months, with benefits sustained through six month follow-up.
Help employers find you! Check out all the jobs and post your resume.
comments powered by